Healthcare Industry News: Imitrex
News Release - April 18, 2012
Aerocrine AB Announces New US LeadershipSOLNA, Sweden--(Healthcare Sales & Marketing Network)--Aerocrine AB (STO:AEROB) announces that Mr. Ken Marshall will assume responsibility for US Operations at Aerocrine, Inc. effectively immediately.
Mr. Marshall has over 20 years of experience in global commercial operations spanning general and specialty businesses for both drug and device. This experience includes marketing, sales, health economic/payer strategy and business development. Prior to joining Aerocrine, Ken was Vice President of Marketing at Ikaria, a critical care company, focusing on the commercialization of a drug/device indicated for the treatment of neonatal hypoxic respiratory failure. He also managed new product strategy and device evolution. In addition, Ken was Vice President of Marketing at GlaxoSmithKline where his primary responsibilities included the launch and commercialization of several key products including Imitrex/Amerge, Vesicare, Zofran and multiple products in the company’s HIV franchise.
Ken holds a BSBA in Marketing and Economics from Western Carolina University and a Masters of Business Administration from Houston Baptist University
“Several Board Members, key members of my leadership team and myself were involved in the search over the past several months and we felt that out of all the candidates reviewed, Ken demonstrated the necessary leadership, broad general management acumen and skills to accelerate our growth and build a high performing organization in the US going forward. “
“Ken knows the respiratory field very well and brings a wealth of small and large company experience to bear here at Aerocrine, Inc. Ken will report to me as the President of the US subsidiary and will be a member of my Executive Leadership team. The US will be our largest market and we have seen a real need to accelerate our activities there. We have spent the last several months gearing up for sustainable growth and this marks a real change of our senior talent to achieve our corporate goals.”Said Scott Myers, CEO, Aerocrine AB
“ I look forward to joining Aerocrine at this important junction of its growth and am excited about helping build a strong, well functioning organization here in the US to ensure we continue to help Physicians make better choices through using Aerocrine’s monitor and tests for their patients” said Ken Marshall.
Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO®. This product enables fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the U.S., Germany and the U.K. Aerocrine shares were listed on the Stockholm Stock Exchange in 2007. Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8:00 a.m. on April 18, 2012.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.